Clinical implications of MTA proteins in human cancer

Cancer and Metastasis Reviews

Volumn 33, Issue 4, 2014, Pages 1017-1024

  Kaur, Ekjot ^a   Gupta, Sudeep ^a   Dutt, Shilpee ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

Biomarker; Chromatin remodeling complex; Clinical implications of MTA proteins; Metastasis; Metastasis associated gene; Tumor progression; Tumorigenesis

Indexed keywords

ESTROGEN RECEPTOR ALPHA; HEPATITIS B VIRUS X PROTEIN; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; ISOPROTEIN; MTA1 PROTEIN; MTA2 PROTEIN; MTA3 PROTEIN; NONHISTONE PROTEIN; NURD COMPLEX; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; PROTEIN; PROTEIN P53; TUMOR PROTEIN; UNCLASSIFIED DRUG; HISTONE DEACETYLASE; MTA1 PROTEIN, HUMAN; MYC PROTEIN; MYC PROTEIN, HUMAN; REPRESSOR PROTEIN; TP53 PROTEIN, HUMAN;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER RESISTANCE; CARCINOGENESIS; COLORECTAL CANCER; EPITHELIAL MESENCHYMAL TRANSITION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; HUMAN; LARGE CELL LYMPHOMA; LARYNX CANCER; LIVER CELL CARCINOMA; MELANOMA; METASTASIS; NASOPHARYNX CARCINOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; PANCREAS CANCER; PANCREAS ISLET CELL TUMOR; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; STOMACH CANCER; THYMOMA; TONSIL CANCER; BIOSYNTHESIS; CHROMATIN ASSEMBLY AND DISASSEMBLY; GENE EXPRESSION REGULATION; GENETICS; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY;

CARCINOGENESIS; CHROMATIN ASSEMBLY AND DISASSEMBLY; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; MI-2 NUCLEOSOME REMODELING AND DEACETYLASE COMPLEX; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84914098166     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-014-9527-z     Document Type: Article

References (101)

1. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646–674.
2. Weinberg, R. A. (1983). Oncogenes and the molecular biology of cancer. Journal of Cell Biology, 97(6), 1661–1662.
3. Ciriello, G., et al. (2013). Emerging landscape of oncogenic signatures across human cancers. Nature Genetics, 45(10), 1127–1133.
4. Esteller, M. (2011). Epigenetic changes in cancer. F1000 Biology Reports, 3, 9.
5. Feinberg, A. P., & Vogelstein, B. (1983). Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature, 301(5895), 89–92.
6. Toh, Y., Pencil, S. D., & Nicolson, G. L. (1994). A novel candidate metastasis-associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression, and protein analyses. Journal of Biological Chemistry, 269(37), 22958–22963.
7. Cui, Q., et al. (2001). Assignment of the human metastasis-associated gene 1 (MTA1) to human chromosome band 14q32.3 by fluorescence in situ hybridization. Cytogenetics and Cell Genetics, 93(1–2), 139–140.
8. Nicolson, G. L., et al. (2003). Tumor metastasis-associated human MTA1 gene and its MTA1 protein product: role in epithelial cancer cell invasion, proliferation and nuclear regulation. Clinical and Experimental Metastasis, 20(1), 19–24.
9. Toh, Y., et al. (1997). Overexpression of the MTA1 gene in gastrointestinal carcinomas: correlation with invasion and metastasis. International Journal of Cancer, 74(4), 459–463.
10. Toh, Y., Pencil S.D., and Nicolson G.L. (1995). Analysis of the complete sequence of the novel metastasis-associated candidate gene, mta1, differentially expressed in mammary adenocarcinoma and breast cancer cell lines. Gene,159(1), 97–104.
11. Manavathi, B., Singh, K., & Kumar, R. (2007). MTA family of coregulators in nuclear receptor biology and pathology. Nuclear Receptor Signaling, 5, e010.
12. Aasland, R., Stewart, A. F., & Gibson, T. (1996). The SANT domain: a putative DNA-binding domain in the SWI-SNF and ADA complexes, the transcriptional co-repressor N-CoR and TFIIIB. Trends in Biochemical Sciences, 21(3), 87–88.
13. Boyer, L. A., et al. (2002). Essential role for the SANT domain in the functioning of multiple chromatin remodeling enzymes. Molecular Cell, 10(4), 935–942.
14. Liu, J., et al. (2014). The subcellular distribution and function of MTA1 in cancer differentiation. Oncotarget, 5(13), 5153–5164.
15. Moon, W. S., Chang, K., & Tarnawski, A. S. (2004). Overexpression of metastatic tumor antigen 1 in hepatocellular carcinoma: relationship to vascular invasion and estrogen receptor-alpha. Human Pathology, 35(4), 424–429.
16. Balasenthil, S., Broaddus, R. R., & Kumar, R. (2006). Expression of metastasis-associated protein 1 (MTA1) in benign endometrium and endometrial adenocarcinomas. Human Pathology, 37(6), 656–661.
17. Fujita, N., et al. (2003). MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell, 113(2), 207–219.
18. Kumar, R., et al. (2002). A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm. Nature, 418(6898), 654–657.
19. Zhang, Y., et al. (1998). The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell, 95(2), 279–289.
20. Xue, Y., et al. (1998). NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities.Molecular Cell, 2(6), 851–861.
21. Zhang, Y., et al. (1999). Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes and Development, 13(15), 1924–1935.
22. Iguchi, H., et al. (2000). Expression of MTA1, a metastasis-associated gene with histone deacetylase activity in pancreatic cancer.International Journal of Oncology, 16(6), 1211–1214.
23. Toh, Y., & Nicolson, G. L. (2009). The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications. Clinical and Experimental Metastasis, 26(3), 215–227.
24. Moon, H. E., Cheon, H., & Lee, M. S. (2007). Metastasis-associated protein 1 inhibits p53-induced apoptosis. Oncology Reports, 18(5), 1311–1314.
25. Yoo, Y. G., Kong, G., & Lee, M. O. (2006). Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1. EMBO Journal, 25(6), 1231–1241.
26. Yoo, Y. G., et al. (2008). Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells. Oncogene, 27(24), 3405–3413.
27. Bui-Nguyen, T. M., et al. (2010). NF-kappaB signaling mediates the induction of MTA1 by hepatitis B virus transactivator protein HBx.Oncogene, 29(8), 1179–1189.
28. Li, W., et al. (2009). Expression profile of MTA1 in adult mouse tissues. Tissue and Cell, 41(6), 390–399.
29. Mazumdar, A., et al. (2001). Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nature Cell Biology, 3(1), 30–37.
30. Zhang, S., et al. (2012). Sertoli cell-specific expression of metastasis-associated protein 2 (MTA2) is required for transcriptional regulation of the follicle-stimulating hormone receptor (FSHR) gene during spermatogenesis. Journal of Biological Chemistry, 287(48), 40471–40483.
31. Dias, S. J., et al. (2013). Nuclear MTA1 overexpression is associated with aggressive prostate cancer, recurrence and metastasis in African Americans. Science Reports, 3, 2331.
32. Hofer, M. D., et al. (2009). Immunohistochemical and clinicopathological correlation of the metastasis-associated gene 1 (MTA1) expression in benign and malignant pancreatic endocrine tumors. Modern Pathology, 22(7), 933–939.
33. Park, J. O., et al. (2011). Relationships between metastasis-associated protein (MTA) 1 and lymphatic metastasis in tonsil cancer.European Archives of Oto-Rhino-Laryngology, 268(9), 1329–1334.
34. Prisco, M. G., et al. (2012). Prognostic role of metastasis tumor antigen 1 in patients with ovarian cancer: a clinical study. Human Pathology, 43(2), 282–288.
35. Tuncay Cagatay, S., et al. (2013). MTA-1 expression is associated with metastasis and epithelial to mesenchymal transition in colorectal cancer cells. Tumour Biology, 34(2), 1189–1204.
36. Higashijima, J., et al. (2011). Expression of histone deacetylase 1 and metastasis-associated protein 1 as prognostic factors in colon cancer. Oncology Reports, 26(2), 343–348.
37. Liu, T., et al. (2013). Metastasis-associated protein 1 is a novel marker predicting survival and lymph nodes metastasis in cervical cancer. Human Pathology, 44(10), 2275–2281.
38. Du, B., et al. (2011). Metastasis-associated protein 1 induces VEGF-C and facilitates lymphangiogenesis in colorectal cancer. World Journal of Gastroenterology, 17(9), 1219–1226.
39. Li, S. H., et al. (2011). Overexpression of metastasis-associated protein 1 is significantly correlated with tumor angiogenesis and poor survival in patients with early-stage non-small cell lung cancer. Annals of Surgical Oncology, 18(7), 2048–2056.
40. Li, S. H., Wang, Z., & Liu, X. Y. (2009). Metastasis-associated protein 1 (MTA1) overexpression is closely associated with shorter disease-free interval after complete resection of histologically node-negative esophageal cancer. World Journal of Surgery, 33(9), 1876–1881.
41. Sharma, G., et al. (2011). Clinical significance of Maspin promoter methylation and loss of its protein expression in invasive ductal breast carcinoma: correlation with VEGF-A and MTA1 expression. Tumour Biology, 32(1), 23–32.
42. Dannenmann, C., et al. (2008). The metastasis-associated gene MTA1 is upregulated in advanced ovarian cancer, represses ERbeta, and enhances expression of oncogenic cytokine GRO. Cancer Biology and Therapy, 7(9), 1460–1467.
43. Agboola, A.O., et al. (2014). Clinicopathological and molecular significance of Sumolyation marker (ubiquitin conjugating enzyme 9 (UBC9)) expression in breast cancer of black women.Pathology - Research and Practice, 210(1),10–7.
44. Liu, S. L., et al. (2012). Expression of metastasis-associated protein 2 (MTA2) might predict proliferation in non-small cell lung cancer. Targeted Oncology, 7(2), 135–143.
45. Zhang, H., Stephens, L. C., & Kumar, R. (2006). Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer. Clinical Cancer Research, 12(5), 1479–1486.
46. Kumar, R., Wang, R. A., & Bagheri-Yarmand, R. (2003). Emerging roles of MTA family members in human cancers. Seminar in Oncology, 30(5 Suppl 16), 30–37.
47. Li, D. Q., et al. (2012). Metastasis-associated protein 1/nucleosome remodeling and histone deacetylase complex in cancer. Cancer Research, 72(2), 387–394.
48. Kumar, R. (2003). Another tie that binds the MTA family to breast cancer. Cell, 113(2), 142–143.
49. Nawa, A., et al. (2000). Tumor metastasis-associated human MTA1 gene: its deduced protein sequence, localization, and association with breast cancer cell proliferation using antisense phosphorothioate oligonucleotides. Journal of Cellular Biochemistry, 79(2), 202–212.
50. Bagheri-Yarmand, R., et al. (2004). Metastasis-associated protein 1 deregulation causes inappropriate mammary gland development and tumorigenesis. Development, 131(14), 3469–3479.
51. Ohshiro, K., et al. (2010). Acetylation-dependent oncogenic activity of metastasis-associated protein 1 co-regulator. EMBO Reports, 11(9), 691–697.
52. Cui, Y., et al. (2006). Metastasis-associated protein 2 is a repressor of estrogen receptor alpha whose overexpression leads to estrogen-independent growth of human breast cancer cells. Molecular Endocrinology, 20(9), 2020–2035.
53. Mishra, S. K., et al. (2004). Upstream determinants of estrogen receptor-alpha regulation of metastatic tumor antigen 3 pathway.Journal of Biological Chemistry, 279(31), 32709–32715.
54. Zhang, H., et al. (2006). Metastatic tumor antigen 3 is a direct corepressor of the Wnt4 pathway. Genes and Development, 20(21), 2943–2948.
55. Gururaj, A. E., et al. (2006). Breast cancer-amplified sequence 3, a target of metastasis-associated protein 1, contributes to tamoxifen resistance in premenopausal patients with breast cancer. Cell Cycle, 5(13), 1407–1410
56. Gururaj, A. E., et al. (2006). MTA1, a transcriptional activator of breast cancer amplified sequence 3. Proceedings of the National Academy of Sciences of the United States of America, 103(17), 6670–6675
57. Nagaraj, S.R., et al. (2013). Crosstalk between VEGF and MTA1 signaling pathways contribute to aggressiveness of breast carcinoma. Molecular Carcinogenesis. doi:10.1002/mc.22104.
58. Kang, H. J., et al. (2014). Differential regulation of estrogen receptor alpha expression in breast cancer cells by metastasis-associated protein 1. Cancer Research, 74(5), 1484–1494.
59. Zhang, X. Y., et al. (2005). Metastasis-associated protein 1 (MTA1) is an essential downstream effector of the c-MYC oncoprotein.Proceedings of the National Academy of Sciences of the United States of America, 102(39), 13968–13973
60. Tang, Z. Y. (2001). Hepatocellular carcinoma—cause, treatment and metastasis. World Journal of Gastroenterology, 7(4), 445–454.
61. Toh, Y., et al. (1999). Overexpression of metastasis-associated MTA1 mRNA in invasive oesophageal carcinomas. British Journal of Cancer, 79(11–12), 1723–1726.
62. LLi, S. H., et al. (2012). Metastasis-associated protein 1 nuclear expression is closely associated with tumor progression and angiogenesis in patients with esophageal squamous cell cancer. World Journal of Surgery, 36(3), 623–631.
63. Weng, W., et al. (2014). Metastasis-associated protein 1 promotes tumor invasion by downregulation of E-cadherin. International Journal of Oncology, 44(3), 812–818.
64. Miyashita, T., et al. (2014). Impact of histone deacetylase 1 and metastasis-associated gene 1 expression in esophageal carcinogenesis. Oncology Letters, 8(2), 758–764.
65. Bagheri-Yarmand, R., et al. (2007). Metastasis-associated protein 1 transgenic mice: a new model of spontaneous B-cell lymphomas. Cancer Research, 67(15), 7062–7067.
66. Balasenthil, S., et al. (2007). Identification of Pax5 as a target of MTA1 in B-cell lymphomas. Cancer Research, 67(15), 7132–7138.
67. Qian, H., et al. (2007). RNA interference of metastasis-associated gene 1 inhibits metastasis of B16F10 melanoma cells in a C57BL/6 mouse model. Biology of the Cell, 99(10), 573–581.
68. Sasaki, H., et al. (2001). Expression of the MTA1 mRNA in thymoma patients. Cancer Letters, 174(2), 159–163.
69. Sasaki, H., et al. (2002). Expression of the MTA1 mRNA in advanced lung cancer. Lung Cancer, 35(2), 149–154.
70. Zhu, X., et al. (2010). Metastasis-associated protein 1 nuclear expression is associated with tumor progression and clinical outcome in patients with non-small cell lung cancer. Journal of Thoracic Oncology, 5(8), 1159–1166.
71. Lin, Z., et al. (2014). EBV-encoded LMP2A Promotes EMT in nasopharyngeal carcinoma via MTA1 and mTOR signaling induction. Journal of Virology, 88(20), 11872–85.
72. Li, Y., et al. (2013). MTA1 promotes the invasion and migration of non-small cell lung cancer cells by downregulating miR-125b.Journal of Experimental & Clinical Cancer Research, 32, 33.
73. Zhang, H., et al. (2014). Metastasis-associated gene 1 promotes invasion and migration potential of laryngeal squamous cell carcinoma cells. Oncology Letters, 7(2), 399–404
74. Lee, S. H., et al. (2012). Single nucleotide polymorphisms associated with metastatic tumour antigen 1 overexpression in patients with hepatocellular carcinoma. Liver International, 32(3), 457–466.
75. Giannini, R., & Cavallini, A. (2005). Expression analysis of a subset of coregulators and three nuclear receptors in human colorectal carcinoma. Anticancer Research, 25(6B), 4287–4292.
76. Toh, Y., et al. (2004). Expression of the metastasis-associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas. International Journal of Cancer, 110(3), 362–367
77. Kidd, M., et al. (2006). The role of genetic markers—NAP1L1, MAGE-D2, and MTA1—in defining small-intestinal carcinoid neoplasia. Annals of Surgical Oncology, 13(2), 253–262.
78. Kidd, M., et al. (2006). Utility of molecular genetic signatures in the delineation of gastric neoplasia. Cancer, 106(7), 1480–1488.
79. Hofer, M. D., et al. (2004). The role of metastasis-associated protein 1 in prostate cancer progression. Cancer Research, 64(3), 825–829.
80. Hamatsu, T., et al. (2003). The role of MTA1 gene expression in human hepatocellular carcinoma. Oncology Reports, 10(3), 599–604.
81. Martin, M. D., et al. (2006). Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Research and Treatment, 95(1), 7–12.
82. Jang, K. S., et al. (2006). MTA1 overexpression correlates significantly with tumor grade and angiogenesis in human breast cancers.Cancer Science, 97(5), 374–379.
83. Covington, K.R., et al.(2013). Metastasis tumor-associated protein 2 enhances metastatic behavior and is associated with poor outcomes in estrogen receptor-negative breast cancer. Breast Cancer Research and Treatment,141(3),375–384.
84. Kai, L., et al. (2011). Targeting prostate cancer angiogenesis through metastasis-associated protein 1 (MTA1). Prostate, 71(3), 268–280.
85. Qian, H., et al. (2005). Reduced MTA1 expression by RNAi inhibits in vitro invasion and migration of esophageal squamous cell carcinoma cell line. Clinical and Experimental Metastasis, 22(8), 653–662.
86. Rao, Y., et al. (2011). Silencing MTA1 by RNAi reverses adhesion, migration and invasiveness of cervical cancer cells (SiHa) viaaltered expression of p53, and E-cadherin/beta-catenin complex. Journal of Huazhong University of Science and Technology. Medical Sciences, 31(1), 1–9.
87. Li, D. Q., et al. (2010). Revelation of p53-independent function of MTA1 in DNA damage response via modulation of the p21 WAF1-proliferating cell nuclear antigen pathway. Journal of Biological Chemistry, 285(13), 10044–10052.
88. Li, D. Q., et al. (2010). Requirement of MTA1 in ATR-mediated DNA damage checkpoint function. Journal of Biological Chemistry, 285(26), 19802–19812.
89. Li, D. Q., et al. (2009). MTA1 coregulator regulates p53 stability and function. Journal of Biological Chemistry, 284(50), 34545–34552.
90. Li, D. Q., & Kumar, R. (2010). Mi-2/NuRD complex making inroads into DNA-damage response pathway. Cell Cycle, 9(11), 2071–2079.
91. Pakala, S. B., et al. (2010). Regulation of NF-kappaB circuitry by a component of the nucleosome remodeling and deacetylase complex controls inflammatory response homeostasis. Journal of Biological Chemistry, 285(31), 23590–23597.
92. Pakala, S. B., et al. (2010). MTA1 coregulator regulates LPS response via MyD88-dependent signaling. Journal of Biological Chemistry, 285(43), 32787–32792.
93. Bui-Nguyen, T. M., et al. (2010). Stimulation of inducible nitric oxide by hepatitis B virus transactivator protein HBx requires MTA1 coregulator. Journal of Biological Chemistry, 285(10), 6980–6986.
94. Nair, S. S., et al. (2011). The metastasis-associated protein-1 gene encodes a host permissive factor for schistosomiasis, a leading global cause of inflammation and cancer. Hepatology, 54(1), 285–295.
95. Nair, S. S., et al. (2011). Inflammatory response to liver fluke Opisthorchis viverrini in mice depends on host master coregulator MTA1, a marker for parasite-induced cholangiocarcinoma in humans. Hepatology, 54(4), 1388–1397.
96. Kai, L., Samuel, S. K., & Levenson, A. S. (2010). Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1/NuRD complex. International Journal of Cancer, 126(7), 1538–1548.
97. Li, K., et al. (2013). Pterostilbene acts through metastasis-associated protein 1 to inhibit tumor growth, progression and metastasis in prostate cancer. PLoS One, 8(3), e57542.
98. Reddy, S. D., et al. (2011). Multiple coregulatory control of tyrosine hydroxylase gene transcription. Proceedings of the National Academy of Sciences of the United States of America, 108(10), 4200–4205.
99. Manavathi, B., et al. (2007). Repression of Six3 by a corepressor regulates rhodopsin expression. Proceedings of the National Academy of Sciences of the United States of America, 104(32), 13128–13133.
100. Li, W., et al. (2008). Involvement of metastasis tumor antigen 1 in hepatic regeneration and proliferation. Cellular Physiology and Biochemistry, 22(1–4), 315–326.
101. Reddy, S. D., et al. (2009). MicroRNA-661, a c/EBPalpha target, inhibits metastatic tumor antigen 1 and regulates its functions. Cancer Research, 69(14), 5639–5642.